340B Drug Pricing Program
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate models” before they can be implemented, which the department has not yet done for any of the models pursued by the plaintiff drug companies.
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-…
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models.
340B Advocacy Alliance Bulletin for May 14, 2025.
AHA, others files brief defending South Dakota's 340B contract pharmacy law.
AHA urges Secretary U.S. Department of Health and Human Services to reject the effort by several large drug companies to undermine the 340B Drug Pricing Program by imposing a “rebate model,”
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house…
AHA, others file brief in defense of Nebraska’s 340B contract pharmacy law.
The AHA on Thursday, May 15 at 3 p.m. ET will host a call for member hospitals and health systems to discuss the Department of Health and Human Services’ recent announcement that it will be “in a position to provide guidance” about the drug industry’s proposed use of “rebate models” by the end of…
The AHA May 1 expressed concerns to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare Drug Price Negotiation Program, explaining ways it undermines the purpose of the 340B Drug Pricing Program.